Last updated: July 28, 2026
Cardene (nicardipine) in 0.83% sodium chloride in plastic container: clinical trials update, market analysis, and launch timing projections
Cardene In 0.83% Sodium Chloride In Plastic Container (nicardipine hydrochloride injection) is an IV calcium channel blocker indicated for hypertension. Commercial demand is tied to perioperative and critical-care use patterns, hospital formulary decisions, and IV vasodilator substitution risk. A reliable clinical-trials and exclusivity timeline cannot be produced from the available record because no trial registries, FDA status, Orange Book/NDA/ANDA identifiers, or current litigation/label-change events are provided.
What clinical trials updates exist for Cardene (nicardipine) injection and are any new studies starting or completing?
No trial-level update can be stated from the available information. A defensible “what’s new” view requires at least one of: ClinicalTrials.gov records, publication identifiers, press releases with dates, or FDA label supplements tied to ongoing studies. None are present in the input record.
Which nicardipine IV studies matter for market uptake (perioperative, ICU, hypertensive emergencies)?
No study-specific mapping to endpoints, populations, or comparators can be produced without trial entries, protocol IDs, or publication metadata.
Are there pediatric, renal/hepatic impairment, or stability/compatibility studies for the 0.83% sodium chloride plastic-container presentation?
No dossier-level evidence is available in the input record.
How big is the market for IV nicardipine (Cardene) and what drives hospital purchasing?
A quantitative market analysis cannot be completed from the available record because it lacks baseline commercialization metrics (US sales, units, channel mix), pricing, procurement contracts, and competitive substitution rates.
What are the main use-case purchase drivers for IV nicardipine in hospitals?
No use-case weightings (OR anesthesia vs ICU vs ED) can be quantified from the provided information.
Which competitors most affect Cardene pricing and volume?
No competitor list tied to the specific IV nicardipine product form (and US market shares) is available in the input record.
When does Cardene (nicardipine) lose exclusivity, and what generic or biosimilar entry risks exist?
No exclusivity timeline can be calculated. The input record does not include the NDA number, application holder, listed patents, or expiration dates, so launch timing projections are not supportable.
What patents protect Cardene injection and the 0.83% sodium chloride plastic-container presentation?
No patent estate data (listed Orange Book patents, expiration dates, claims scope) is present in the input record.
Are Paragraph IV ANDA challenges filed for IV nicardipine products?
No litigation or notice-of-certification data is provided.
What is the Orange Book status of nicardipine injection in 0.83% sodium chloride plastic container?
Orange Book listing status cannot be verified from the available record.
What regulatory status does Cardene (nicardipine) have at FDA, including label and manufacturing changes for the plastic-container presentation?
No FDA pathway status, approval history, REMS applicability, or label-change timeline can be provided because the input record does not include NDA/label identifiers, FDA supplement numbers, or postmarketing safety updates.
Is this product still marketed under the same NDA, or has it transitioned to new packaging/manufacturing sources?
No packaging transition history is available in the input record.
How does Cardene compare with alternative IV antihypertensives (clevidipine, labetalol, nitroprusside) in clinical practice and formulary access?
A comparative market projection requires evidence on guideline adherence, cost-per-treatment, availability, contraindication handling, and formulary tiering. None of those inputs are available in the provided record.
Does administration method or compatibility influence substitution for the plastic container / 0.83% sodium chloride formulation?
No compatibility or administration evidence is present in the input record.
What patent litigation affects nicardipine injection, and what settlement terms influence generic entry?
No litigation records, docket identifiers, court venues, or settlement dates are included in the input record.
What generic launch scenarios are most likely for IV nicardipine, and what timelines should investors or business planners model?
No modeled timeline can be produced without: (1) patent expiration dates, (2) exclusivity end dates, (3) ANDA status/approval dates, and (4) any 505(b)(2) or 505(j) pathways relevant to the exact presentation. The input record provides none of these.
Key Takeaways
- Cardene In 0.83% Sodium Chloride In Plastic Container is a nicardipine IV antihypertensive, but no reliable clinical-trials update, exclusivity timeline, Orange Book/patent estate, litigation, or market sizing can be stated from the information provided.
- Launch and generic-entry projections cannot be produced without NDA/patent and FDA status identifiers.
FAQs
- What is the FDA approval history for nicardipine hydrochloride injection in 0.83% sodium chloride plastic container?
- Which patents are listed in the Orange Book for IV nicardipine products, and when do they expire?
- Have any generic ANDAs for IV nicardipine been submitted or received Paragraph IV certifications?
- What clinical trials compare nicardipine IV to clevidipine or labetalol in hypertensive emergencies?
- How do hospital formularies typically decide between IV nicardipine and alternative antihypertensives on cost and protocol fit?
References
- No citable sources were provided in the input record.
